Boehringer Ingelheim Throws Its Humira Biosimilar Hat Into The Ring

Boehringer Ingelheim is poised to submit marketing applications in the US and Europe for its biosimilar adalimumab after it showed equivalent safety and efficacy to Humira in a pivotal study.